East Hartford Dialysis Center is a medicare approved dialysis facility center in East Hartford, Connecticut and it has 24 dialysis stations. It is located in Hartford county at 200 Pitkin Street, East Hartford, CT, 06108. You can reach out to the office of East Hartford Dialysis Center at (860) 282-6266. This dialysis clinic is managed and/or owned by Fresenius Medical Care. East Hartford Dialysis Center has the following ownership type - Profit. It was first certified by medicare in February, 1994. The medicare id for this facility is 072509 and it accepts patients under medicare ESRD program.
| Name | East Hartford Dialysis Center |
|---|---|
| Location | 200 Pitkin Street, East Hartford, Connecticut |
| No. of Dialysis Stations | 24 |
| Medicare ID | 072509 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 200 Pitkin Street, East Hartford, Connecticut, 06108 | |
| (860) 282-6266 | |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| NPI Number | 1407889876 |
| Organization Name | Fresenius Medical Care East Hartford |
| Doing Business As | Bio-medical Applications Of Connecticut, Inc. |
| Address | 200 Pitkin St East Hartford, Connecticut, 06108 |
| Phone Number | (860) 282-6266 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 62% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 27% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 44% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 30% | 14% |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 61% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 15% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 24% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 49% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 12% |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 72% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 28% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 47% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 36% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 70 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 123 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1065 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 32 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 203 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 92 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at East Hartford Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 158 |
| Hypercalcemia patient months | 1358 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 161 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 105 |
| Patient months included in arterial venous fistula and catheter summaries | 755 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 112 |
| Hospitalization Rate in facility | 178.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 290.9 |
| Hospitalization Rate: Lower Confidence Limit | 118.3 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at East Hartford Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.5 |
| Readmission Rate: Lower Confidence Limit | 19.8 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at East Hartford Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .12 (Better than Expected) |
| SIR: Upper Confidence Limit | .61 |
| SIR: Lower Confidence Limit | .01 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether East Hartford Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 90 |
| Transfusion Rate in facility | 22.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 61.5 |
| Transfusion Rate: Lower Confidence Limit | 9.1 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at East Hartford Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 537 |
| Mortality Rate in facility | 16.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21 |
| Mortality Rate: Lower Confidence Limit | 12.7 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago
East Hartford Dialysis Center Location: 200 Pitkin Street, East Hartford, Connecticut, 06108 Phone: (860) 282-6266 |
News Archive
The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Nurses appear to be taking far better care of their patients than they are their financial futures, according to a survey released today by the Center for American Nurses and the Women's Institute for a Secure Retirement (WISER).
› Verified 2 days ago